Ask about this productRelated genes to: MAGEA11 antibody
- Gene:
- MAGEA11 NIH gene
- Name:
- MAGE family member A11
- Previous symbol:
- MAGE11
- Synonyms:
- MAGE-11, MAGEA-11, MGC10511, CT1.11
- Chromosome:
- Xq28
- Locus Type:
- gene with protein product
- Date approved:
- 1994-04-04
- Date modifiied:
- 2015-11-13
Related products to: MAGEA11 antibody
Related articles to: MAGEA11 antibody
- Osteosarcoma (OS) is the most common primary malignant bone tumor in adolescents, characterized by high heterogeneity and poor prognosis. Efferocytosis, the clearance of apoptotic cells, has been implicated in tumor progression and immune evasion, but its role in OS remains unclear. - Source: PubMed
Publication date: 2026/01/22
Song XueliangTou XiaofanLi LiWang FengxianQian ChengqunWang RuShen Jiahong - Osteosarcoma (OS) is a bone malignancy among adolescents with a poor prognosis. We aimed to explore the glycosylation-related features in OS. - Source: PubMed
Publication date: 2026/01/05
Li XiangmingYang ZihanGu XinyuSong YanhuaSun JiachunMa Fuqiang - This study aims to identify novel biomarkers for the early diagnosis of lung adenocarcinoma (LUAD), with the goal of facilitating early intervention to improve patient prognosis. - Source: PubMed
Publication date: 2026/01/05
Huang ShuyuGan YuhanZhong RuifangWang SiyingKang YanliChen JinhuaChen FalinChen LiangyuanYou Jianbin - Proteolysis targeting chimeras (PROTACs) are an emerging therapeutic modality that induces protein degradation by recruiting E3 ligases. Most reported PROTACs recruit ubiquitously expressed E3 ligases, such as cereblon and the von Hippel-Lindau tumor suppressor. Of the additional 600+ E3 ligases, recruiting those with tissue-restricted expression is attractive for increasing the specificity of PROTACs. To this end, tissue-specific E3 ligases or E3 ligase-associated proteins that can be recruited for targeted protein degradation need to be identified. This work describes the first reported PROTAC that recruits the tissue-specific E3 ligase scaffolding protein MAGEA11. As an initial demonstration, a library of bromodomain and extra-terminal domain (BET)-targeting PROTACs that recruit MAGEA11 was synthesized. The library was screened in osteosarcoma U2OS cells, identifying lead compound 105B. 105B potently degrades BET proteins in U2OS osteosarcoma cell lines (BRD4 DC = 0.130 nM, D = 78%) and KYSE180 esophageal squamous cell carcinoma cell lines (DC = 40 nM, D = 70%), but shows no degradation in non-cancerous, MAGEA11-deficient HEK293T cells. Mechanistic studies confirmed 105B's dependence on the ubiquitin-proteasome system and engagement of both MAGEA11 and BRD4. 105B decreased levels of BET-regulated gene products c-Myc, RUNX2, and KRT14; however, improvements are still necessary to affect selective cytotoxicity. This work reports the first example of a PROTAC recruiting a tissue-specific E3 ligase for cancer-restricted degradation of BET proteins and highlights the need for further development of MAGEA11-recruiting degraders. - Source: PubMed
Publication date: 2025/11/03
Jacobsen Isabella EShi RuiScholtz Cole RPomerantz William C KGeorg Gunda I - Gastric cancer (GC) is a prevalent gastrointestinal malignancy in China. Despite advancements in multidisciplinary diagnosis and treatment strategies, the 5-year survival rate remains low at just 10-20%. A significant number of patients ultimately die from postoperative recurrence and distant metastasis. Therefore, it is crucial to investigate the core mechanisms underlying GC development and progression and to identify potential molecular targets for early diagnosis, prevention, and treatment. MAGEA11, part of the melanoma-associated antigen (MAGE) gene family, is associated with several cancers. However, its expression, function, and mechanisms in GC remain unclear. In this study, we first confirmed that MAGEA11 is highly expressed in GC through data analysis from The Cancer Genome Atlas (TCGA), univariate and multivariate Cox regression analyses, and Kaplan-Meier survival curve analysis. Our findings indicate that MAGEA11 is an independent prognostic factor for overall survival (OS) in GC patients, with higher expression levels correlating with shorter OS, disease-specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI). Next, we explored the role of MAGEA11 in GC by constructing stable cell models with MAGEA11 knockdown and overexpression. Functional assays on these models demonstrated that MAGEA11 promotes the proliferation, migration, and invasion of GC cells in vitro. Additionally, the tumor-promoting effects of MAGEA11 were verified in vivo using a GC cell tumor model. Previous studies have shown that MAGEA11 increases the transcriptional activity of the transcription factor E2F1, thereby promoting cancer progression. To verify this mechanism in GC, we conducted cell function experiments and immunohistochemistry, confirming that MAGEA11 promotes GC development by activating E2F1's transcriptional activity. These findings indicate that MAGEA11 may be a useful molecular marker for predicting GC prognosis. - Source: PubMed
Publication date: 2025/11/21
Shen QichengLu ZhouDai LingchenHuang XinkunFeng Ying